Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in japanese patients with benign prostatic hyperplasia

Urology

Volumn 78, Issue 5, 2011, Pages 1058-1062

  Tsujimura, Akira ^a   Takao, Tetsuya ^a   Miyagawa, Yasushi ^a   Okuda, Hidenobu ^a   Yamamoto, Keisuke ^a   Fukuhara, Shinichiro ^a   Nakayama, Jiro ^a   Ueda, Tomohiro ^a   Kiuchi, Hiroshi ^a   Hirai, Toshiaki ^a   Tsujimoto, Yuichi ^b   Miura, Hidenobu ^c   Kanno, Nobuteru ^d   Higashino, Makoto ^e   Nakamura, Yoshihiro ^f   Nishimura, Kenji ^g   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI SENRI HOSPITAL   (Japan)

^c Miura Clinic   (Japan)

^d Kanno Clinic   (Japan)

^e Higashino Clinic   (Japan)

^f Department of Urology   (Japan)

^g Hyogo Prefectural Nishinomiya Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TAMSULOSIN;

ADULT; AGED; ANNOYANCE; ARTICLE; BENIGN PROSTATIC HYPERTROPHY IMPACT INDEX; BOTHERSOMENESS; CONTROLLED STUDY; DRUG EFFECT; HEALTH SURVEY; HUMAN; INDEPENDENT VARIABLE; JAPANESE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OVERACTIVE BLADDER; OVERACTIVE BLADDER SYMPTOM SCORE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; TREATMENT DURATION; URINARY URGENCY; URINE INCONTINENCE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; HUMANS; MALE; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; URINARY BLADDER, OVERACTIVE;

EID: 80455173869     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.05.032     Document Type: Article

References (30)

1. S.J. Berry, D.S. Coffey, and P.C. Walsh The development of human benign prostatic hyperplasia with age J Urol 132 1984 474 479 (Pubitemid 14026148)
2. R.R. Berges, L. Pientka, and K. Hofner Male lower urinary tract symptoms and related health care seeking in Germany Eur Urol 39 2001 682 687 (Pubitemid 32679638)
3. S.J. Jacobsen, C.J. Girman, and H.A. Guess Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms Urology 42 1993 663 671 (Pubitemid 24004787)
4. F.J. Fowler Jr, J.E. Wennberg, and R.P. Timothy Symptom status and quality of life following prostatectomy JAMA 259 1988 3018 3022
5. AUA Practice Guidelines Committee AUA Guideline on Management of Benign Prostatic Hyperplasia (2003) Chapter 1: diagnosis and treatment recommendations J Urol 170 2003 530 547
6. T.J. Peters, J.L. Donovan, and H.E. Kay The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms J Urol 157 1997 885 889 (Pubitemid 27066273)
7. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society Neurourol Urodyn 21 2002 167 178 (Pubitemid 34195211)
8. Y. Homma, O. Yamaguchi, and K. Hayashi An epidemiological survey of overactive bladder symptoms in Japan BJU Int 96 2005 1314 1318 (Pubitemid 41743931)
9. I. Milsom, P. Abrams, and L. Cardozo How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760 766 (Pubitemid 34204313)
10. W.F. Stewart, J.B. Van Rooyen, and G.W. Cundiff Prevalence and burden of overactive bladder in the United States World J Urol 20 2003 327 336 (Pubitemid 44175300)
11. P. Abrams, C.J. Kelleher, and L.A. Kerr Overactive bladder significantly affects quality of life Am J Manag Care 6 2000 S580 S590
12. D.E. Irwin, I. Milsom, and Z. Kopp Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder Eur Urol 56 2009 14 20
13. M.J. Barry, F.J. Fowler Jr, and M.P. O'Leary Measuring disease-specific health status in men with benign prostatic hyperplasia Measurement Committee of the American Urological Association Med Care 33 1995 AS145 AS155
14. Y. Homma, M. Yoshida, and N. Seki Symptom assessment tool for overactive bladder syndromeoveractive bladder symptom score Urology 68 2006 318 323 (Pubitemid 44175525)
15. Y. Homma, and M. Gotoh Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int 104 2009 968 972
16. K.E. Andersson, C.R. Chapple, and K. Hofner Future drugs for the treatment of benign prostatic hyperplasia World J Urol 19 2002 436 442
17. J.Y. Lee, H.W. Kim, and S.J. Lee Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder BJU Int 94 2004 817 820 (Pubitemid 39472476)
18. A. Tsujimura, T. Takao, and H. Okuda Survey of lower urinary tract symptoms in patients with benign prostatic hyperplasia and usefulness of tamsulosin hydrochloride Jpn J Urol Surg 23 2010 301 308
19. A. Tsujimura, T. Takao, and Y. Miyagawa Urgency is an independent factor for sleep disturbance in men with obstructive sleep apnea Urology 76 2010 967 970
20. Y. Homma, H. Kakizaki, and O. Yamaguchi Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score Urology 77 2011 60 64
21. K.S. Coyne, C. Payne, and S.K. Bhattacharyya The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey Value Health 7 2004 455 463 (Pubitemid 39038454)
22. A. Tubaro Defining overactive bladder: epidemiology and burden of disease Urology 64 2004 2 6 (Pubitemid 40038567)
23. H. Lepor Tamsulosin Investigator Group Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia Urology 51 1998 892 900 (Pubitemid 28240845)
24. H. Lepor Tamsulosin Investigator Group Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial Urology 51 1998 901 906 (Pubitemid 28240846)
25. M.C. Michel, L. Mehlburger, and H.U. Bressel Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160 1998 784 791 (Pubitemid 29479514)
26. P. Narayan, and H. Lepor Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia Urology 57 2001 466 470 (Pubitemid 32192976)
27. C.C. Schulman, J. Cortvriend, U. Jonas European Tamsulosin Study Group Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study Eur Urol 36 1999 609 620 (Pubitemid 29516293)
28. M.T. Flannery, J. Ramsdell, and A. Ranhosky Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting Curr Med Res Opin 22 2006 721 730
29. K. Ichioka, H. Ohara, and N. Terada Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia Int J Urol 11 2004 870 875 (Pubitemid 39490738)
30. A. Bertaccini, F. Vassallo, and F. Martino Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH Eur Urol 40 Suppl 1 2001 13 18 (Pubitemid 34701700)